Svar Life Science

White Paper

Advancing Monoclonal Antibodies Development with iLite® Complement-Dependent Cytotoxicity (CDC) Bioassay

Are you developing the next generation of therapeutic antibodies?

You know then that it's often difficult to evaluate Fc effector activities and determine which of these effects is prevalent in the mode of action in a rapid, reliable, robust, and reproducible way. Here, you can learn more about the relevance of antibody-induced complement‐dependent cytotoxicity (CDC) and how to measure the potency of CDC induction or inhibition using an advanced functional bioassay that goes beyond interaction to support biologics development. 

Dive deep into cutting-edge therapeutic antibody development with our latest whitepaper, now available for download. 

White Paper

Advancing Monoclonal Antibodies Development with iLite® Complement-Dependent Cytotoxicity (CDC) Bioassay

Are you developing the next generation of therapeutic antibodies?

You know then that it's often difficult to evaluate Fc effector activities and determine which of these effects is prevalent in the mode of action in a rapid, reliable, robust, and reproducible way. Here, you can learn more about the relevance of antibody-induced complement‐dependent cytotoxicity (CDC) and how to measure the potency of CDC induction or inhibition using an advanced functional bioassay that goes beyond interaction to support biologics development. 

Dive deep into cutting-edge therapeutic antibody development with our latest whitepaper, now available for download. 

This comprehensive white paper delves into the intricacies of assessing antibody-mediated CDC activity, showcasing the iLite CDC platform's exceptional accuracy, efficiency, and adaptability in developing transformative therapeutic monoclonal antibodies.

- Gain insights into the high linearity between antibody concentrations and Svar luciferase quantification, which is crucial for precise CDC activity assessment.
- Learn about the robustness of the iLite CDC bioassay, designed to accommodate a wide range of serum concentrations without compromising on performance.
- Explore how our cell engineering expertise enables the customization of the bioassay platform to suit any surface antigen, providing unparalleled support and flexibility.

The iLite CDC Bioassay platform offers a comprehensive solution for evaluating complement-dependent cytotoxicity. Whether you're involved in novel therapeutic monoclonal antibody development seeking to enhance CDC activity or looking to inhibit CDC activity, our whitepaper is an essential resource for empowering your projects in the diverse landscape of disease treatment.

Download our whitepaper today and take the first step towards harnessing the full potential of antibody-mediated CDC in your research endeavors.

 

Please complete the form to access the white paper